Semaglutide was originally approved by the FDA approved in 2014 for Type 2 diabetes to lower blood sugar and maintain blood sugar levels. Over time, it was discovered that Semaglutide had other benefits such as improved cardiovascular risk, decreased inflammation, decreased appetite, and thus weight loss. Semaglutide was FDA approved in 2019 for use in patients with a BMI of 30 or greater, or a BMI of 27 and greater with at least one comorbidity, for weight management.

Semaglutide is a glucagon-like peptide-1 receptor agonist. It mimics the action of the incretin GL-1 by increasing the production of insulin or a hormone that lowers blood sugar levels. Semaglutide works by suppressing your appetite, and the peptide semaglutide mimics acts on the areas in the brain that regulate appetite and food intake. The peptide semaglutide imitates GL-1 and targets the areas in the brain that regulate appetite and food intake.
In addition to the use of Semaglutide, use of an exercise program and reduced caloric intake will help aid in weight loss goals and long-term management.